Overcoming Resistance to Drugs Targeting KRASG12C Mutation
Activating KRAS mutations are present in 25% of human cancer. Although oncogenic Ras was deemed “undruggable” in the past, recent efforts led to the development of pharmacological inhibitors targeting the KRASG12C mutant, which have shown promise in early clinical trials. The development of allele-s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-08-01
|
| Series: | The Innovation |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666675820300357 |